Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →
Help us improve your experience. Please confirm your investor type:
Global ETF Survey 2026
The ETF Industry Is Evolving Fast
From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.
BBC ETF · Virtus LifeSci Biotech Clinical Trials ETF
The BBC Exchange Traded Fund (ETF) is provided by VIRTUS Investment Partners. It is built to track an index: LifeSci Biotechnology Clinical Trials Index. The BBC ETF provides physical exposure, so by buying it you actually own parts of all the 117 underlying holdings. This share class generates a stream of income by distributing dividends.
Last update Yesterday at 1:30 PM UTC
LIVE
CLOSED
This fund is part ofTomorrow's Treatments1M perf.+10.15%
Last price
$52.79
1M perf.
+17.61%
1M flows
+€475K
AuM
€45M
TER
0.65%
Rating
BBC
$52.79
Performance & flows
Segment for quartile rank
April 1, 2026 → July 1, 2026
Create a free account to view the flows graph
BBC
$51.64
+22.07%
Tomorrow's Treatments
+13.06%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +17.61%  | +22.07% | +170.36% | +121.60% | +4.24% | -2.03% | -2.03% | +33.41% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
More details
NAV
7/1/2026
$51.61
1D NAV change
-2.04%
Dividend policy
Replication method
Direct (Physical)
Replication model
Full replication
No. of holdings
117
Inception date
12/16/2014
Jurisdiction
United States
Distribution
United States
Legal structure
Statutory Trust
Base currency
USD
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Product type
Asset class
Factors
N/A
Investment strategy
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index, which tracks the performance of select clinical trials stage biotechnology companies.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialAdvertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +22.07% | +170.36% | +121.60% | +4.24% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Countries
USA
84.40%
United Kingdom
3.17%
Netherlands
2.72%
Ireland
2.14%
Canada
2.09%
Unavailable
3.35%
Other
2.13%
Sectors
Healthcare
96.65%
Unavailable
3.35%
Diversification
Total weight of top 15 holdings out of 117
Top 15 holdings
Data as of May 31, 2026
Create a free account to view top holdings
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Replication
Trackinsight replication rating:
1-year trailing difference
As of June 30, 2026
Create a free account to view the replication graph
BBC
N/A
Replication quality
Calculated over 12m, as of June 30, 2026
Tracking error
Tracking difference
1-year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Replication information
Index
Index ticker
Index dividend policy
Replication method
Replication model
Issuer
VIRTUS Investment Partners
VIRTUS Investment Partners ID Card
Number of funds
23
Total AuM
€2.49B
Expense ratio range
0.25% - 10.6%
Average expense ratio
0.9474%
Top 5 funds by VIRTUS Investment Partners
| AuM | ||
|---|---|---|
UTES | Virtus Reaves Utilities ETF | €1.2B |
NFLT | Virtus Newfleet Multi-Sector Bond ETF | €386M |
SEIX | Virtus Seix Senior Loan ETF | €220M |
JOET | Virtus Terranova U.S. Quality Momentum ETF | €214M |
VABS | Virtus Newfleet ABS/MBS ETF | €99M |
Frequently asked questions about BBC
What does Virtus LifeSci Biotech Clinical Trials ETF, BBC, invest in?
BBC is a Passive ETF. This ETF provides exposure to Equally Weighted US Equities.
Which benchmark or index does BBC replicate?
BBC tracks the LifeSci Biotechnology Clinical Trials Total Return Index - USD, through a full replication replication method.
What is the Total Expense ratio (TER) of BBC?
BBC carries a total expense ratio (TER) of 0.65%, indicating the annual cost for holding the fund.
When was BBC launched?
BBC was introduced to the market on December 16, 2014. It trades on United States
Who is the ETF issuer of BBC?
Virtus LifeSci Biotech Clinical Trials ETF, BBC, is provided by VIRTUS Investment Partners. Learn more about VIRTUS Investment Partners here.
What is the current assets under management (AUM) of BBC?
BBC oversees €45M in assets as of July 1, 2026.
How has BBC performed lately?
Based on data from July 1, 2026, BBC returned 17.61% over the past month, 22.07% over the last three months and 33.41% year-to-date.
What are the latest inflows or outflows for BBC?
As of July 1, 2026, BBC recorded net flows of +€504K over the last month and +€6.1M year-to-date.
Does BBC distribute dividends?
BBC follows a distributing dividend policy, meaning it pays out income to investors. As of July 1, 2026, its 12-month trailing yield was 1.27%.
What are the main country or region exposures of BBC?
As of May 31, 2026, BBC has significant geographic allocations in USA, United Kingdom and Netherlands.
In which sector or theme does BBC invest in?
As of May 31, 2026, BBC focuses largely on Healthcare.
How many securities does BBC hold and how diversified is it?
As of May 31, 2026, BBC holds 117 positions in its portfolio, with 22.05% of assets concentrated in its top 15 holdings.
What are the main positions in BBC?
As of May 31, 2026, BBC top three holdings include Enliven Therapeutics, Inc., Spyre Therapeutics, Inc. and Tango Therapeutics, Inc..
What is the base currency of BBC?
The base currency of BBC is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
